Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1976 1
2000 1
2001 2
2002 3
2003 1
2004 4
2006 1
2007 3
2008 4
2009 2
2010 2
2011 3
2012 4
2013 1
2014 4
2015 4
2016 8
2017 6
2018 8
2019 5
2020 6
2021 7
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

77 results
Results by year
Filters applied: . Clear all
Page 1
Recurrent Glioblastoma Treated with Recombinant Poliovirus.
Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Desjardins A, et al. N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26. N Engl J Med. 2018. PMID: 29943666 Free PMC article. Clinical Trial.
We conducted a dose-finding and toxicity study in this population of patients, evaluating convection-enhanced, intratumoral delivery of the recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO). PVSRIPO recognizes the poliovirus receptor CD155, which is widely expre …
We conducted a dose-finding and toxicity study in this population of patients, evaluating convection-enhanced, intratumoral delivery of the …
Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.
Brown MC, Gromeier M. Brown MC, et al. Curr Opin Virol. 2015 Aug;13:81-5. doi: 10.1016/j.coviro.2015.05.007. Epub 2015 Jun 12. Curr Opin Virol. 2015. PMID: 26083317 Free PMC article. Review.
An oncolytic virus (OV) based on poliovirus (PV), the highly attenuated polio/rhinovirus recombinant PVSRIPO, may deliver targeted inflammatory cancer cell killing; a principle that is showing promise in clinical trials for recurrent glioblastoma (GBM). ...
An oncolytic virus (OV) based on poliovirus (PV), the highly attenuated polio/rhinovirus recombinant PVSRIPO, may deliver targ …
Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.
Brown MC, Gromeier M. Brown MC, et al. Discov Med. 2015 May;19(106):359-65. Discov Med. 2015. PMID: 26105699 Free PMC article. Review.
A natural ability to recruit effector responses makes tumor-targeting ('oncolytic') viruses attractive as immunotherapy vehicles. However, most viruses actively block inflammatory and immunogenic events; or, host innate immune responses may prevent immune initiating events …
A natural ability to recruit effector responses makes tumor-targeting ('oncolytic') viruses attractive as immunotherapy vehicles. How …
Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.
Goetz C, Gromeier M. Goetz C, et al. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):197-203. doi: 10.1016/j.cytogfr.2010.02.005. Epub 2010 Mar 17. Cytokine Growth Factor Rev. 2010. PMID: 20299272 Free PMC article. Review.
PVS-RIPO is a genetically recombinant, non-pathogenic poliovirus chimera with a tumor-specific conditional replication phenotype. ...In this review we summarize advances in the understanding of major molecular determinants of PVS-RIPO oncolytic efficacy and safety a …
PVS-RIPO is a genetically recombinant, non-pathogenic poliovirus chimera with a tumor-specific conditional replication phenotype. ... …
Oncolytic poliovirus against malignant glioma.
Goetz C, Dobrikova E, Shveygert M, Dobrikov M, Gromeier M. Goetz C, et al. Future Virol. 2011 Sep;6(9):1045-1058. doi: 10.2217/fvl.11.76. Future Virol. 2011. PMID: 21984883 Free PMC article.
We describe a novel experimental cancer therapy approach based on genetically recombinant poliovirus that targets an intriguing aberration of translation control in malignancy. ...PVSRIPO, a prototype nonpathogenic poliovirus recombinant, is scheduled to enter clini …
We describe a novel experimental cancer therapy approach based on genetically recombinant poliovirus that targets an intriguing aberr …
Recombinant Poliovirus for Cancer Immunotherapy.
Gromeier M, Nair SK. Gromeier M, et al. Annu Rev Med. 2018 Jan 29;69:289-299. doi: 10.1146/annurev-med-050715-104655. Annu Rev Med. 2018. PMID: 29414253 Free PMC article. Review.
In this review, we explain the mechanisms of recombinant nonpathogenic poliovirus, PVSRIPO, which is currently in phase I clinical trials against recurrent glioblastoma. We focus on an unusual host:virus relationship defined by the simple and cytotoxic replication strategy …
In this review, we explain the mechanisms of recombinant nonpathogenic poliovirus, PVSRIPO, which is currently in phase I clinical tr …
Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.
Walton RW, Brown MC, Sacco MT, Gromeier M. Walton RW, et al. J Virol. 2018 Sep 12;92(19):e00879-18. doi: 10.1128/JVI.00879-18. Print 2018 Oct 1. J Virol. 2018. PMID: 29997212 Free PMC article.
We are pursuing cancer immunotherapy with a neuro-attenuated recombinant poliovirus, PVSRIPO. PVSRIPO is the live attenuated type 1 (Sabin) poliovirus vaccine carrying a heterologous internal ribosomal entry site (IRES) of human rhinovirus type 2 (HRV2). ...This has …
We are pursuing cancer immunotherapy with a neuro-attenuated recombinant poliovirus, PVSRIPO. PVSRIPO is the live attenuated type 1 ( …
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma.
Lupo KB, Matosevic S. Lupo KB, et al. J Hematol Oncol. 2020 Jun 12;13(1):76. doi: 10.1186/s13045-020-00913-2. J Hematol Oncol. 2020. PMID: 32532329 Free PMC article. Review.
Though still emerging, cancer immunotherapies utilizing NK cells are proving promising as a modality for the treatment of a number of solid tumors, including glioblastoma (GBM) and other gliomas, but are often limited due to complex immunosuppression associated with the GBM tumor …
Though still emerging, cancer immunotherapies utilizing NK cells are proving promising as a modality for the treatment of a number of solid …
Oncolytic Activity of the Vaccine Strain of Type 3 Poliovirus on the Model of Rat Glioma C6 Cells.
Sosnovtseva AO, Zheltukhin AO, Lipatova AV, Chumakov PM, Chekhonin VP. Sosnovtseva AO, et al. Bull Exp Biol Med. 2019 May;167(1):111-115. doi: 10.1007/s10517-019-04472-6. Epub 2019 Jun 8. Bull Exp Biol Med. 2019. PMID: 31177454
Rat glioma cell line C6 expressing human poliovirus receptor (PVR) and susceptible to polioviruses (C6-PVR-BFP) was used to produce a clone with knockout of IFNalpha/beta (Ifnar1) receptor subunit 1 gene (Ifnar1). The sensitivity of C6-PVR-BFP cells to the vaccine s …
Rat glioma cell line C6 expressing human poliovirus receptor (PVR) and susceptible to polioviruses (C6-PVR-BFP) was used to pr …
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Foreman PM, Friedman GK, Cassady KA, Markert JM. Foreman PM, et al. Neurotherapeutics. 2017 Apr;14(2):333-344. doi: 10.1007/s13311-017-0516-0. Neurotherapeutics. 2017. PMID: 28265902 Free PMC article. Review.
The concept of virotherapy for the treatment of malignant tumors dates back more than a century and can be divided into replication-competent oncolytic viruses and replication-deficient viral vectors. Oncolytic viruses are designed to selectively target, infect, and …
The concept of virotherapy for the treatment of malignant tumors dates back more than a century and can be divided into replication-competen …
77 results